Currently, the only potential indicative biomarker for LAM that exists is vascular endothelial growth factor-D (VEGF-D); it has been found that serum levels of VEGF-D are elevated in some patients with LAM [10]. The gene discussed is VEGFD; the disease is lymphangioleiomyomatosis.